Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: BIOLOGICAL: OPT-822/OPT-821(30 μg/100 μg)|BIOLOGICAL: Phosphate Buffer Saline (PBS)|DRUG: Cyclophosphamide
Sponsor: OBI Pharma, Inc